Peter Molloy on the Nasodine SARS-CoV-2 data and the Firebrick vision

  10 Feb 2022

“Our goal is to create a successful Australian pharmaceutical business that is globally-facing…and I hope that in the next five years we will see Nasodine sold in most countries around the world.”